
## Lidia Ciszak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4854334/publications.pdf Version: 2024-02-01



LIDIA CISZAK

#	Article	IF	CITATIONS
1	Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients. International Journal of Molecular Sciences, 2021, 22, 9298.	4.1	8
2	BTLA Expression in CLL: Epigenetic Regulation and Impact on CLL B Cell Proliferation and Ability to IL-4 Production. Cells, 2021, 10, 3009.	4.1	5
3	Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients. Journal of Immunology Research, 2020, 2020, 1-12.	2.2	20
4	Imbalance in PB IL-17-Secreting and Regulatory Cells in Pars Planitis Is Associated with Dysregulation of IFN-Î <sup>3</sup> -Secreting Cells, Especially in Patients with Clinical Complications. Mediators of Inflammation, 2020, 2020, 1-9.	3.0	2
5	CD4+CD28null T cells are expanded in moderately active systemic lupus erythematosus and secrete pro-inflammatory interferon gamma, depending on the Disease Activity Index. Lupus, 2020, 29, 705-714.	1.6	14
6	Dysregulated interferon Î <sup>3</sup> and interleukin 2 synthesis in peripheral blood T cells in quiescent systemic lupus erythematosus is dependent on the affected T cell receptor ζ chain expression. Polish Archives of Internal Medicine, 2018, 128, 626-630.	0.4	0
7	CTLA-4 affects expression of key cell cycle regulators of G0/G1 phase in neoplastic lymphocytes from patients with chronic lymphocytic leukaemia. Clinical and Experimental Medicine, 2016, 16, 317-332.	3.6	11
8	Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody. Tumor Biology, 2016, 37, 4143-4157.	1.8	22
9	Pretransplant donor and recipient CTLA-4 mRNA and protein levels as a prognostic marker for aGvHD in allogeneic hematopoietic stem cell transplantation. Immunology Letters, 2015, 165, 52-59.	2.5	7
10	Exogenous IL-2 Controls the Balance in Th1, Th17, and Treg Cell Distribution in Patients with Progressive Rheumatoid Arthritis Treated with TNF-Alpha Inhibitors. Inflammation, 2015, 38, 765-774.	3.8	20
11	Alterations in Both the Activatory and Inhibitory Potential of Peripheral Blood CD4+ T Cells in Rheumatoid Arthritis Patients Correlate with Disease Progression. Pathology and Oncology Research, 2014, 20, 235-243.	1.9	6
12	Patients with the most advanced rheumatoid arthritis remain with Th1 systemic defects after TNF inhibitors treatment despite clinical improvement. Rheumatology International, 2014, 34, 243-253.	3.0	13
13	Peripheral blood Th17/Treg imbalance in patients with low-active systemic lupus erythematosus. Postepy Higieny I Medycyny Doswiadczalnej, 2014, 68, 893-898.	0.1	32
14	Dysregulated Expression of Both the Costimulatory CD28 and Inhibitory CTLA-4 Molecules in PB T Cells of Advanced Cervical Cancer Patients Suggests Systemic Immunosuppression Related to Disease Progression. Pathology and Oncology Research, 2012, 18, 479-489.	1.9	29
15	Zeta chain expression in T and NK cells in peripheral blood of children with nephrotic syndrome. Pediatric Nephrology, 2010, 25, 119-127.	1.7	6
16	High intracellular content of cyclin-dependent kinase inhibitor p27Kip1in early- and intermediate stage B-cell chronic lymphocytic leukemia lymphocytes predicts rapid progression of the disease. European Journal of Haematology, 2009, 82, 260-266.	2.2	12
17	The <i>CTLAâ€4</i> gene polymorphisms are associated with CTLAâ€4 protein expression levels in multiple sclerosis patients and with susceptibility to disease. Immunology, 2009, 128, e787-96.	4.4	43
18	Is Cyclin D2 a Marker of B-CLL Cell Activation?. Oncology Research, 2009, 18, 127-131.	1.5	2

LIDIA CISZAK

#	Article	IF	CITATIONS
19	Impaired zeta chain expression and IFN-gamma production in peripheral blood T and NK cells of patients with advanced lung cancer. Oncology Reports, 2009, 21, 173-84.	2.6	15
20	The significance of Treg cells in defective tumor immunity. Archivum Immunologiae Et Therapiae Experimentalis, 2008, 56, 181-191.	2.3	65
21	CD28 downregulation on CD4+T cells is associated with age of kidney transplant recipient. Transplant International, 2008, 21, 661-668.	1.6	4
22	Alterations in the expression of signal-transducing CD3ζ chain in T cells from patients with chronic inflammatory/autoimmune diseases. Archivum Immunologiae Et Therapiae Experimentalis, 2007, 55, 373-386.	2.3	20
23	CD40L, CD28, and CTLA-4 expression on CD4+ T cells in kidney graft recipients: A relationship with post-transplantation clinical course. Transplant Immunology, 2006, 16, 32-40.	1.2	12
24	Carp liver DNase—isolation, further characterization and interaction with endogenous actin. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2005, 140, 141-151.	1.6	5
25	Correlation of blood lymphocyte CTLA-4 (CD152) induction in Hodgkin's disease with proliferative activity, interleukin 2 and interferon-gamma production. British Journal of Haematology, 2002, 118, 202-209.	2.5	19
26	Carp liver actin: isolation, polymerization and interaction with deoxyribonuclease I (DNase I). Biochimica Et Biophysica Acta - Molecular Cell Research, 1999, 1451, 141-152.	4.1	5

3